Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Treilleux

Showing results (161-170 of 186) with videos related to

Pageof 19
Sort By:
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Cancers|January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG NetworkClémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Genes, Chromosomes & Cancer|January 26, 2022
Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosisNicolas Macagno, Daniel Pissaloux, Arnaud de la Fouchardière, et al.
Gynecologic Oncology|October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 29, 2017
Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS<sup>G12D</sup>-driven Pancreatic TumorigenesisNicolas Chuvin, David F Vincent, Roxane M Pommier, et al.
NPJ Breast Cancer|April 17, 2021
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohortThomas Grinda, Natacha Joyon, Amélie Lusque, et al.
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
Pageof 19

Showing results (161-170 of 186) with videos related to

Sort By:
Pageof 19
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
British Journal of Cancer|October 13, 2017
Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcomaCarmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, et al.
Breast Cancer Research and Treatment|May 4, 2015
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialBrian Leyland-Jones, Kathryn P Gray, Mark Abramovitz, et al.
Cancers|January 21, 2022
Therapeutic Challenges in Patients with Gynecologic Carcinosarcomas: Analysis of a Multicenter National Cohort Study from the French Prospective TMRG NetworkClémence Romeo, Olivia Le Saux, Margaux Jacobs, et al.
Genes, Chromosomes & Cancer|January 26, 2022
Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosisNicolas Macagno, Daniel Pissaloux, Arnaud de la Fouchardière, et al.
Gynecologic Oncology|October 26, 2021
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)Olivier Trédan, Magali Provansal, Cyril Abdeddaim, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 29, 2017
Acinar-to-Ductal Metaplasia Induced by Transforming Growth Factor Beta Facilitates KRAS<sup>G12D</sup>-driven Pancreatic TumorigenesisNicolas Chuvin, David F Vincent, Roxane M Pommier, et al.
NPJ Breast Cancer|April 17, 2021
Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohortThomas Grinda, Natacha Joyon, Amélie Lusque, et al.
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Nature Communications|July 16, 2024
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinomaOlivia Le Saux, Maude Ardin, Justine Berthet, et al.
Pageof 19